SRPT
What one share of Sarepta Therapeutics holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $17.56 |
|---|---|
| Profit | −$0.86 |
| Capex (buildings and equipment) | $0.26 |
| Free cash flow | $0.73 |
| Cash and investments | $5.41 |
| Debt | $8.02 |
| Book value | $14.46 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.11 | −$5.49 | $0.11 | −$5.16 | — | $6.15 |
| 2017 | $2.63 | −$0.86 | $0.20 | −$4.15 | — | $12.18 |
| 2018 | $4.54 | −$5.46 | $0.92 | −$6.79 | — | $14.52 |
| 2019 | $5.17 | −$9.71 | $0.81 | −$7.01 | — | $10.88 |
| 2020 | $6.93 | −$7.11 | $1.05 | $0.32 | — | $9.60 |
| 2021 | $8.64 | −$5.15 | $0.47 | −$5.93 | — | $10.65 |
| 2022 | $10.66 | −$8.03 | $0.35 | −$4.07 | — | $4.38 |
| 2023 | $13.46 | −$5.80 | $0.82 | −$6.25 | — | $9.17 |
| 2024 | $17.63 | $2.34 | $1.27 | −$3.18 | — | $15.77 |
| 2025 | $21.96 | −$7.13 | $1.02 | −$3.07 | — | $10.87 |